




PHARMACEUTICAL 2022

Blueprint Medicines Corp
Rank 221 of 466





PHARMACEUTICAL 2022

Blueprint Medicines Corp
Rank 221 of 466



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Blueprint Medicines Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 56% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	554,025
Cost of Goods Sold	17,934
Intangible Assets	0
Liabilities, Current	149,765
Liabilities, Non-Current	131,725
Other Assets	667,500
Other Compr. Net Income	1,081
Other Expenses	10,802
Other Liabilities	0
Other Net Income	897
Other Revenues	180,080
Property and Equipment	30,700
Research and Development	601,033
Selling, General and Administrative Expense	195,293

Output Variable	Value in 1000 USD
Assets	1,252,225
Liabilities	281,490
Expenses	825,062
Revenues	180,080
Stockholders Equity	970,735
Net Income	-644,085
Comprehensive Net Income	-643,544
Economic Capital Ratio	134%